作者: Zheng Wu , Dan Zhu
DOI: 10.3109/1354750X.2014.950331
关键词:
摘要: Catestatin (CST) was first discovered as a potent non-competitive and reversible inhibitor of catecholamine secretion. Recent reports on plasma CST level in heart diseases suggested cardioprotective role for this peptide. Given that cardiac remodeling is the dominant pathologic process dysfunction, we propose participates regulation concern pathways contributes to inhibition remodeling. In minireview, potential mechanism involving will be discussed from three aspects: hypertrophy, fibrosis, apoptosis.